Gestrinone
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Gestrinone
UNSPSC Description:
Gestrinone (R2323) is a synthetic steroid hormone used to treat endometriosis. It inhibits leiomyoma cells with an IC50 of 43.67 μM. Gestrinone is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.Target Antigen:
Estrogen Receptor/ERRType:
Reference compoundRelated Pathways:
Vitamin D Related/Nuclear ReceptorApplications:
COVID-19-immunoregulationField of Research:
Inflammation/ImmunologyAssay Protocol:
https://www.medchemexpress.com/Gestrinone.htmlPurity:
99.76Solubility:
DMSO : ≥ 50 mg/mL|H2O : < 0.1 mg/mLSmiles:
C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3C=C[C@]12CC)=OMolecular Weight:
308.41References & Citations:
[1]Tamaya T, et al. Gestrinone (R2323) binding to steroid receptors in human uterine endometrial cytosol. Acta Obstet Gynecol Scand. 1986;65(5):439-41.|[2]Zhu Y, et al. Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ERα, Src and P38 MAPK. Biomed Pharmacother. 2012 Dec;66(8):569-77.|[3]Snyder BW, et al. Studies on the mechanism of action of danazol and gestrinone (R2323) in the rat: evidence for a masked estrogen component. Fertil Steril. 1989 Apr;51(4):705-10.|[4]Dowsett M, et al. A comparison of the effects of danazol and gestrinone on testosterone binding to sex hormone binding globulin in vitro and in vivo. Clin Endocrinol (Oxf). 1986 May;24(5):555-63.Shipping Conditions:
Blue IceStorage Conditions:
-20°C, 3 years (Powder)Clinical Information:
LaunchedCAS Number:
16320-04-0
